Amgen Dirección
Dirección controles de criterios 3/4
El CEO de Amgen es Bob Bradway , nombrado en May 2012, tiene una permanencia de 14.17 años. compensación anual total es $24.69M, compuesta por 7.8% salario y 92.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.11% de las acciones de la empresa, por valor de $225.63M. La antigüedad media del equipo directivo y de la junta directiva es de 6.5 años y 9.4 años, respectivamente.
Información clave
Bob Bradway
Chief Executive Officer (CEO)
US$24.7m
Compensación total
| Porcentaje del salario del CEO | 7.80% |
| Permanencia del CEO | 14.2yrs |
| Participación del CEO | 0.1% |
| Permanencia media de la dirección | 6.5yrs |
| Promedio de permanencia en la Junta Directiva | 9.4yrs |
Actualizaciones recientes de la dirección
Recent updates
Actualización de narrativa • Jul 10
AMGN: IRS Dispute And Regulatory Setbacks Will Pressure Future Returns
Amgen's updated analyst price target now reflects a fair value estimate of $252.61. Analysts point to refined revenue and margin assumptions, a slightly higher discount rate, and sector-level research that highlights both supportive biotech conditions and company-specific model updates following recent earnings and regulatory disclosures.Seeking Alpha • Jun 26
Amgen Continues To Perform
Summary Amgen is rated between Hold and Buy, with shares potentially slightly undervalued or fairly valued depending on free cash flow assumptions. Newer products like Repatha, Evenity, and Tezspire are driving double-digit growth, offsetting steep declines from legacy drugs Enbrel and Prolia. Management guides 2026 revenue of $37.1–$38.5B and non-GAAP EPS of $21.70–$23.10, reflecting steady but moderate growth. Balance sheet caution is warranted due to $57B in debt, though a robust pipeline and possible upside from MariTide support long-term optimism. Read the full article on Seeking AlphaActualización de narrativa • Jun 14
AMGN: IRS Dispute And Tax Overhang Will Pressure Future Returns
Narrative Update on Amgen Analysts have adjusted Amgen's fair value estimate by about $1 to $244.55 as they balance a lower discount rate and slightly higher projected profit margins against more cautious revenue growth assumptions and recent shifts in Street price targets tied to the ramp of Uplizna and ongoing IRS dispute commentary. Analyst Commentary Recent Street research on Amgen has been mixed, with some firms raising price targets around the launch of Uplizna in generalized myasthenia gravis and others trimming targets as they factor in tax uncertainty and differing views on long term growth drivers.
Actualización de narrativa • May 31
AMGN: Fair Outlook Balances Rare Disease Potential With Expanded Manufacturing Investment
Amgen's fair value estimate has shifted modestly higher to about $352 per share, up from roughly $350. This reflects analysts' mixed price target revisions around $427 and updated expectations for rare disease and other growth drivers.Actualización de narrativa • May 14
AMGN: Fair Outlook Weighs Pipeline Execution Against Expanded Manufacturing Commitments
Analysts have nudged the Amgen price target slightly lower to about $350. This reflects a modest increase in the discount rate, slightly softer revenue growth assumptions and a small reduction in the future P/E multiple, partly offset by a higher projected profit margin and a mix of recent upgrades, downgrades and price target revisions across the Street.Actualización de narrativa • Apr 28
AMGN: Recent Rally And Trial Uncertainty Will Pressure Future Returns
Amgen's fair value estimate has moved from about $230.89 to $243.49 as analysts factor in a series of higher price targets from firms across the Street, balanced by several neutral initiations. These initiations point to solid fundamentals but mixed views on potential upside from this level.
Actualización de narrativa • Apr 14
AMGN: Diversified Autoimmune And Cardiovascular Pipeline Will Support Future Cash Generation
Analysts have lifted Amgen's average price target, with changes such as the recent $10, $17, $6, $10 and $15 upward revisions reflecting updated views on its pipeline progress, commercial execution, and refreshed financial models. Analyst Commentary Recent Street research on Amgen shows a cluster of higher price targets and fresh coverage that centers on its pipeline, commercial performance, and updated financial models.Actualización de narrativa • Mar 30
AMGN: Obesity And Cardiovascular Pipeline Will Support Future Cash Generation
Analysts kept the $432 price target for Amgen steady, reflecting a balance between recent target increases tied to pipeline and commercial updates, and newer Hold and Equal Weight initiations that describe the shares as fairly valued after a strong run. Analyst Commentary Recent research on Amgen shows a mix of optimism and caution around valuation, with bullish analysts highlighting commercial execution and the expanding pipeline, while newer initiations frame the shares as fairly valued after a strong move higher.Actualización de narrativa • Mar 16
AMGN: Fair Outlook Balances Patent Expiries With Late Stage Pipeline Potential
The Analyst Price Target for Amgen has been updated from $327.74 to $350.03 as analysts factor in recent price target increases tied to stronger near term commercial execution, added value from key Phase 3 pipeline assets, and a shift toward discounted cash flow based models that emphasize improved margin assumptions and a slightly lower discount rate. Analyst Commentary Recent Street commentary around Amgen reflects a mix of optimism about the current execution and pipeline, alongside ongoing debate about valuation, product risks, and long term earnings durability.Actualización de narrativa • Mar 02
AMGN: Obesity And Cardiovascular Pipeline Will Drive Future Cash Generation
The analyst price target for Amgen in this narrative has moved to $432. Analysts point to updated DCF assumptions, slightly lower revenue growth and profit margin inputs, and a modestly higher future P/E multiple supported by recent price target increases across the Street and ongoing confidence in the pipeline and guidance.Actualización de narrativa • Feb 16
AMGN: Long Patent Expiries And Heavier Spending Will Pressure Future Earnings
Analysts have lifted their price targets on Amgen by about $12 to reflect updated views on fair value, profitability, and future P/E assumptions, while also factoring in a higher discount rate and lower projected revenue growth. Analyst Commentary Recent research on Amgen points to a split view, with several firms lifting price targets while others are turning more cautious.Artículo de análisis • Feb 11
Amgen (NASDAQ:AMGN) Is Increasing Its Dividend To $2.52
Amgen Inc.'s ( NASDAQ:AMGN ) dividend will be increasing from last year's payment of the same period to $2.52 on 6th of...Actualización de narrativa • Feb 02
AMGN: Obesity And Cardiovascular Pipeline Will Shape Long-Term Cash Generation
Analysts have nudged their Amgen price targets higher by about $10 to $20, citing a shift toward discounted cash flow analysis, steady execution in legacy products, and increased confidence in the obesity and cardiovascular pipeline. Analyst Commentary Recent research on Amgen highlights a wide range of opinions, but there is a clear cluster of bullish analysts who are leaning into higher price targets and more constructive ratings.Artículo de análisis • Jan 21
Amgen's (NASDAQ:AMGN) Shareholders Will Receive A Bigger Dividend Than Last Year
Amgen Inc. ( NASDAQ:AMGN ) has announced that it will be increasing its dividend from last year's comparable payment on...Actualización de narrativa • Jan 19
AMGN: Obesity And Cardiovascular Pipeline Will Support Long-Term Upside Potential
Analysts have raised their price targets on Amgen into a higher range, with moves such as BofA's shift to a discounted cash flow approach and UBS's upgraded view on earnings and pipeline potential, even as others highlight upcoming patent expiries and spending needs that temper expectations. Analyst Commentary Recent research on Amgen shows a mix of cautious and constructive views, but the price target moves cluster in a higher range, with several firms now anchoring their models around pipeline contributions and cash flow potential alongside the existing portfolio.Artículo de análisis • Jan 07
Amgen (NASDAQ:AMGN) Is Increasing Its Dividend To $2.52
Amgen Inc. ( NASDAQ:AMGN ) will increase its dividend from last year's comparable payment on the 6th of March to $2.52...Actualización de narrativa • Jan 05
AMGN: Patent Expiries And New Drug Launches Will Shape Future Performance
Analysts nudged their fair value estimate for Amgen higher to about $328 per share, up from roughly $323. This reflects slightly firmer revenue expectations and a higher assumed future P/E, balanced against more conservative profit margin assumptions and mixed Street views that highlight both the stability of the core business and uncertainty around patent expiries and new launches.Actualización de narrativa • Dec 15
AMGN: Margin Expansion And Pipeline Progress Will Drive Long-Term Upside Potential
Analysts have nudged their fair value estimate for Amgen higher to approximately $425 from about $405, reflecting a more constructive view on the company as a defensive large cap biotech with improving margin potential and an innovation pipeline that, while still facing patent expiry and execution risks, is increasingly seen as capable of supporting long term earnings power. Analyst Commentary Recent Street research on Amgen highlights a balanced but gradually improving sentiment backdrop, with a growing cohort of bullish analysts positioning the company as a core large cap biotech holding.Actualización de narrativa • Nov 30
AMGN: Future Pipeline Progress And Revenue Diversification Will Shape Performance
Amgen's analyst price target has been raised modestly to $322.88, with analysts citing stable revenue, recent guidance increases, and optimism around its pipeline despite ongoing challenges related to patent expiries. Analyst Commentary Recent Street research provides a nuanced view of Amgen’s valuation, outlook, and potential risk factors, with opinions split between those optimistic about its growth trajectory and those concerned about near-term challenges.Actualización de narrativa • Nov 16
AMGN: Future Pipeline Progress And Profit Margins Will Guide Near-Term Performance
Amgen's fair value target has increased by approximately $7 to $318.51, as analysts highlight robust profit margin improvement and sustained pipeline progress in their latest updates. Analyst Commentary Recent updates from Wall Street reveal a mix of optimism and caution surrounding Amgen’s outlook.Artículo de análisis • Aug 13
Statutory Profit Doesn't Reflect How Good Amgen's (NASDAQ:AMGN) Earnings Are
Even though Amgen Inc. ( NASDAQ:AMGN ) posted strong earnings, investors appeared to be underwhelmed. We have done some...Artículo de análisis • Aug 01
Is Amgen (NASDAQ:AMGN) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Seeking Alpha • Apr 17
Amgen: The Biotech That Knows How To Make Money
Summary Amgen's strategic growth through M&A and R&D investments has led to a diversified portfolio, with significant contributions from rare disease treatments and biosimilars. Financially robust, Amgen achieved record revenues of $33.4 billion in 2024, with strong EBITDA growth and high free cash flow, despite increased debt from acquisitions. The company's balanced business model and innovative pipeline, including promising drugs in oncology and cardiometabolic diseases, support a "Buy" rating with a 16.44% growth potential. Key risks include expiring patents and regulatory pressures, but Amgen's diversified strategy and strong cash flow position it well for future growth. Read the full article on Seeking AlphaNueva narrativa • Apr 08
Biosimilar Competition And TEPEZZA Approvals Will Define Future Path
Declining prices combined with biosimilar competition and loss of exclusivity threaten revenue growth and profit margins.Nueva narrativa • Apr 08
Expanding Oncology Portfolio And International Launches Will Unlock Potential
Expansion in oncology and rare diseases, coupled with strategic pipeline innovations, promises substantial long-term revenue and earnings growth.Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$8b |
| Dec 31 2025 | US$25m | US$2m | US$8b |
| Sep 30 2025 | n/a | n/a | US$7b |
| Jun 30 2025 | n/a | n/a | US$7b |
| Mar 31 2025 | n/a | n/a | US$6b |
| Dec 31 2024 | US$24m | US$2m | US$4b |
| Sep 30 2024 | n/a | n/a | US$4b |
| Jun 30 2024 | n/a | n/a | US$3b |
| Mar 31 2024 | n/a | n/a | US$4b |
| Dec 31 2023 | US$23m | US$2m | US$7b |
| Sep 30 2023 | n/a | n/a | US$8b |
| Jun 30 2023 | n/a | n/a | US$8b |
| Mar 31 2023 | n/a | n/a | US$8b |
| Dec 31 2022 | US$21m | US$2m | US$7b |
| Sep 30 2022 | n/a | n/a | US$7b |
| Jun 30 2022 | n/a | n/a | US$7b |
| Mar 31 2022 | n/a | n/a | US$6b |
| Dec 31 2021 | US$22m | US$2m | US$6b |
| Sep 30 2021 | n/a | n/a | US$6b |
| Jun 30 2021 | n/a | n/a | US$6b |
| Mar 31 2021 | n/a | n/a | US$7b |
| Dec 31 2020 | US$20m | US$2m | US$7b |
| Sep 30 2020 | n/a | n/a | US$7b |
| Jun 30 2020 | n/a | n/a | US$7b |
| Mar 31 2020 | n/a | n/a | US$8b |
| Dec 31 2019 | US$20m | US$2m | US$8b |
Compensación vs. Mercado: La compensación total de Bob($USD24.69M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD14.67M).
Compensación vs. Ingresos: La compensación de Bob ha sido consistente con los resultados de la empresa en el último año.
CEO
Bob Bradway (63 yo)
14.2yrs
Permanencia
US$24,693,120
Compensación
Mr. Robert A. Bradway, also known as Bob, has been the Chief Executive Officer of Amgen Inc. since May 23, 2012 and served as its President since May 2010 until May 2012. Mr. Bradway is responsible for the...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman & CEO | 14.2yrs | US$24.69m | 0.11% $ 225.6m | |
| Executive VP & CFO | 6.5yrs | US$8.61m | 0.0074% $ 14.6m | |
| Executive Vice President of Global Markets and Policy | 7.8yrs | US$8.52m | 0.0076% $ 14.9m | |
| EVP of Research & Development | 1.6yrs | US$8.64m | 0.0013% $ 2.6m | |
| Executive Vice President of Operations | 10yrs | US$7.21m | 0.014% $ 27.4m | |
| Chief Accounting Officer & VP of Finance | 2.9yrs | sin datos | 0.00058% $ 1.1m | |
| SVP & Chief Technology Officer | less than a year | sin datos | sin datos | |
| Senior VP & Chief Information Officer | 1.7yrs | sin datos | sin datos | |
| Senior VP of Global Research & Chief Scientific Officer | 1.6yrs | sin datos | sin datos | |
| Executive Director of Investor Relations | no data | sin datos | sin datos | |
| Executive VP | 11yrs | US$7.24m | 0.0059% $ 11.5m | |
| Senior VP of Worldwide Compliance & Business Ethics and Chief Compliance Officer | 6.5yrs | sin datos | 0.0011% $ 2.2m |
6.5yrs
Permanencia media
58.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de AMGN es experimentado (6.5 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman & CEO | 14.8yrs | US$24.69m | 0.11% $ 225.6m | |
| Lead Independent Director | 13.6yrs | US$449.91k | 0.0015% $ 2.9m | |
| Co-Chair of the Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 6yrs | US$379.90k | 0.000080% $ 157.0k | |
| Independent Director | 9.4yrs | US$393.69k | 0.00023% $ 451.4k | |
| Independent Director | 12.8yrs | US$399.90k | 0.0026% $ 5.0m | |
| Independent Director | 9.8yrs | US$400.17k | 0.000080% $ 157.0k | |
| Independent Director | 8.2yrs | US$379.91k | 0.00040% $ 785.0k | |
| Independent Director | 14.2yrs | US$380.13k | 0.00064% $ 1.3m | |
| Independent Director | 8.6yrs | US$369.91k | 0.0015% $ 2.9m | |
| Member of Scientific Advisory Board of Cardiovascular & Metabolic | 2.5yrs | US$59.67k | sin datos | |
| Co-Chair of the Scientific Advisory Board | less than a year | sin datos | sin datos |
9.4yrs
Permanencia media
70yo
Promedio de edad
Junta con experiencia: La junta directiva de AMGN se considera experimentada (9.4 años de antigüedad promedio).
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/07/10 04:27 |
| Precio de las acciones al final del día | 2026/07/10 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también contamos con guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Amgen Inc. está cubierta por 61 analistas. 31 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| David Toung | Argus Research Company |
| Brian Skorney | Baird |
| Emily Field | Barclays |